Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Cryosurvival of Embryos From Dysmorphic Oocytes

This study has been completed.
Sponsor:
Information provided by:
V.K.V. American Hospital, Istanbul
ClinicalTrials.gov Identifier:
NCT00521443
First received: August 24, 2007
Last updated: NA
Last verified: August 2007
History: No changes posted
  Purpose

Various morphological abnormalities of human oocytes were reported to detrimentally affect embryo development. We observed development of frozen thawed embryos derived from oocytes with normal or abnormal morphological features to the blastocyst stage. Cytoplasmic abnormalities of the oocytes were found to negatively affect cryosurvival potential of the embryos.


Condition Intervention
Cryopreservation
Blastocyst
Procedure: Cryopreservation, thawing and blastocyst culture

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal

Further study details as provided by V.K.V. American Hospital, Istanbul:

Groups/Cohorts Assigned Interventions
Control: Normal
Embryos derived from morphologically normal MII oocytes
Procedure: Cryopreservation, thawing and blastocyst culture
Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.
Case: Irregular Shapes
Embryos derived from irregularly shaped oocytes.
Procedure: Cryopreservation, thawing and blastocyst culture
Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.
Case: Large PVS
Embryos derived from oocytes with large perivitelline space.
Procedure: Cryopreservation, thawing and blastocyst culture
Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.
Case: Dark Zona
Embryos derived from oocytes with dark zona pellucida
Procedure: Cryopreservation, thawing and blastocyst culture
Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.
Case: Dark cytoplasm
Embryos derived from oocytes with dark cytoplasm
Procedure: Cryopreservation, thawing and blastocyst culture
Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.
Case: Vacuolar cytoplasm
Embryos derived from oocytes with vacuolated cytoplasm
Procedure: Cryopreservation, thawing and blastocyst culture
Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.
Case: Central granulation
Embryos derived from oocytes with centrally granulated cytoplasm
Procedure: Cryopreservation, thawing and blastocyst culture
Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.
Case: Double extra
Embryos derived from oocytes with double extracytoplasmic abnormalities
Procedure: Cryopreservation, thawing and blastocyst culture
Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.
Case: Double combined
Embryos derived from oocytes with any combination of one extracytoplasmic and one cytoplasmic anomaly
Procedure: Cryopreservation, thawing and blastocyst culture
Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.
Case: Double cytoplasmic
Embryos derived from oocytes with any two cytoplasmic anomalies
Procedure: Cryopreservation, thawing and blastocyst culture
Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.
Case: Triple extra
Embryos derived from oocytes with triple extracytoplasmic anomaly
Procedure: Cryopreservation, thawing and blastocyst culture
Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.
Case: Triple combined
Embryos derived from oocytes with triple combined anomalies
Procedure: Cryopreservation, thawing and blastocyst culture
Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Female
Criteria

Inclusion Criteria:

  • Human embryos derived from morphologically normal or abnormal mature oocytes that fertilized normally by microinjection procedure.
  • Embryos were obtained from couples who refused to freeze their supernumerary embryos after fresh embryo transfer in an assisted reproduction treatment cycle.

Exclusion Criteria:

  • Embryos obtained after microinjection to immature oocytes taht were in vitro matured in culture.
  • Embryos obtained from abnormally fertilized zygotes.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00521443

Locations
Turkey
VKV American Hospital
Istanbul, Turkey, 34365
Sponsors and Collaborators
V.K.V. American Hospital, Istanbul
Investigators
Study Director: Basak Balaban, B.Sc. Assisted Reproduction Unit of the VKV American Hospital of Istanbul
  More Information

No publications provided by V.K.V. American Hospital, Istanbul

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00521443     History of Changes
Other Study ID Numbers: AH-05/04
Study First Received: August 24, 2007
Last Updated: August 24, 2007
Health Authority: Turkey: Ministry of Health

ClinicalTrials.gov processed this record on November 20, 2014